Skip to main content

Kadcyla Side Effects

Generic name: ado-trastuzumab emtansine

Medically reviewed by Last updated on Apr 29, 2024.

Note: This document contains side effect information about ado-trastuzumab emtansine. Some dosage forms listed on this page may not apply to the brand name Kadcyla.

Applies to ado-trastuzumab emtansine: intravenous powder for solution.


Intravenous route (Powder for Solution)

Do not substitute ado-trastuzumab emtansine with or for trastuzumab. Hepatotoxicity, liver failure, reductions in left ventricular ejection fraction, and death have occurred in ado-trastuzumab emtansine-treated patients. Monitor hepatic function and left ventricular function before beginning treatment and before each dose. Modify, hold, or discontinue treatment as necessary. Exposure to ado-trastuzumab emtansine during pregnancy can result in embryo-fetal harm. Advise patients of these risks and the need for effective contraception.

Serious side effects of Kadcyla

Along with its needed effects, ado-trastuzumab emtansine (the active ingredient contained in Kadcyla) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ado-trastuzumab emtansine:

More common

Less common


Incidence not known

Other side effects of Kadcyla

Some side effects of ado-trastuzumab emtansine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to ado-trastuzumab emtansine: intravenous powder for injection.


Common (1% to 10%): Left ventricular dysfunction, hypertension, peripheral edema[Ref]


Very common (10% or more): Rash (12%)

Common (1% to 10%): Pruritus, alopecia, nail disorder, palmar-plantar erythrodysesthesia syndrome, urticaria[Ref]


Very common (10% or more): Nausea (40%), constipation (24%), vomiting (20%), diarrhea (20%), dry mouth (16%), abdominal pain (16%), stomatitis (15%), stomatitis

Common (1% to 10%): Dyspepsia, gingival bleeding[Ref]


Very common (10% or more): Urinary tract infection (12%)[Ref]


Very common (10% or more): Hemorrhage (35%), thrombocytopenia (25%), anemia (15%), hemorrhage

Common (1% to 10%): Neutropenia, leucopenia[Ref]


Very common (10% or more): Transaminases increased (12%)

Common (1% to 10%):

Uncommon (0.1% to 1%): Hepatotoxicity, hepatic failure, nodular regenerative hyperplasia, portal hypertension

Rare (0.01% to 0.1%): Portal hypertension, hepatic failure, nodular regenerative hyperplasia[Ref]


Common (1% to 10%): Hypersensitivity[Ref]


Common (1% to 10%): Immunogenicity[Ref]


Very common (10% or more): Hypokalemia (11%)

Common (1% to 10%): Blood alkaline phosphatase increased[Ref]


Very common (10% or more): Musculoskeletal pain (36%), arthralgia (19%), myalgia (13%)[Ref]

Nervous system

Very common (10% or more): Headache (28%), peripheral neuropathy (23%), asthenia, chills

Common (1% to 10%): Dizziness, dysgeusia, memory impairment[Ref]


Common (1% to 10%): Dry eye, conjunctivitis, blurred vision, lacrimation increased[Ref]


Very common (10% or more): Fatigue (37%), pyrexia (23%), asthenia (16%), chills (10%)[Ref]


Very common (10% or more): Insomnia (12%)[Ref]


Very common (10% or more): Epistaxis (24%), cough (20%), dyspnea (13%)

Uncommon (0.1% to 1%): Pneumonitis[Ref]


Uncommon (0.1% to 1%): Injection site extravasation, infusion-related reactions[Ref]

Frequently asked questions


1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

2. Cerner Multum, Inc. "Australian Product Information."

3. (2022) "Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.